Portfolio 1 - New Portfolio

John Bender

Portfolio 1
Individual Investor
Ranked #207,658 out of 757,311 TipRanks' Investors
Success Rate
53%
134 out of 253
profitable transactions
Average Return
11.77%
Average return
per transaction
Share this portfolio:

Portfolio Gain

1-Month Return▲ 6.24%
6-Month Return▲ 6.27%
12-Month Return▲ 27.88%
YTD Return▲ 13.61%
Total Return▲ 116.46%

Best Trade

Opened at
Closed at
Gain▲ 538.65%

Bio

Income-focused Retirement Portfolio with speculative bio/pharma, EV and space positions

Performance

25.76%0-25.76%
▲ 14.08%
▲ 5.22%
▲ 10.93%
Feb 2024
▲ 5.05%
▲ 3.27%
▲ 1.33%
Mar 2024
▼ 12.40%
▼ 4.03%
▼ 7.50%
Apr 2024
▲ 11.46%
▲ 5.06%
▲ 7.40%
May 2024
▼ 2.25%
▲ 3.53%
▼ 4.35%
Jun 2024
▲ 25.76%
▲ 1.21%
▲ 8.72%
Jul 2024
▼ 4.21%
▲ 2.34%
▼ 4.01%
Aug 2024
▲ 2.65%
▼ 0.40%
▲ 4.95%
Sep 2024
TipRanks AverageS&P 500Investor Portfolio
▲ 14.08%▲ 5.22%▲ 10.93%
▲ 5.05%▲ 3.27%▲ 1.33%
▼ 12.40%▼ 4.03%▼ 7.50%
▲ 11.46%▲ 5.06%▲ 7.40%
▼ 2.25%▲ 3.53%▼ 4.35%
▲ 25.76%▲ 1.21%▲ 8.72%
▼ 4.21%▲ 2.34%▼ 4.01%
▲ 2.65%▼ 0.40%▲ 4.95%

Recent Activity

Company Name
% of Portfolio
Return
No. of Transactions
Last Transaction
Date
Atara Biotherapeutics
▼ 94.80%
4
Close
Feb 18, 2024
Agenus
▼ 83.14%
3
Close
Feb 18, 2024
Carnival
▼ 5.19%
4
Close
Feb 18, 2024
ImmunoGen
▲ 538.65%
4
Close
Feb 18, 2024
Caribou Biosciences
▼ 29.06%
2
Close
Feb 18, 2024
Crinetics Pharmaceuticals
▲ 104.88%
2
Close
Feb 18, 2024
Cyclo Therapeutics
▼ 6.88%
2
Close
Feb 18, 2024
Precision BioSciences
▼ 71.79%
3
Close
Feb 18, 2024
Capital Southwest
▲ 45.75%
2
Close
Feb 18, 2024
Axsome Therapeutics
▲ 105.56%
3
Close
Feb 18, 2024
Spyre Therapeutics
▼ 9.83%
2
Close
Feb 18, 2024
Allogene Therapeutics
▼ 38.85%
3
Close
Feb 18, 2024
Alpine Immune Sciences
▲ 428.93%
2
Close
Feb 18, 2024
Altimmune
▲ 23.95%
3
Close
Feb 18, 2024
ProShares MSCI Transformational Changes ETF
▲ 31.56%
2
Close
Feb 18, 2024
ARK Innovation ETF
▲ 31.48%
3
Close
Feb 18, 2024
Arcutis Biotherapeutics
▼ 41.09%
3
Close
Feb 18, 2024
Astra Space
▼ 79.27%
3
Close
Feb 18, 2024
Anavex Life Sciences
▼ 53.41%
2
Close
Feb 18, 2024
Ares Capital
▲ 17.86%
3
Close
Feb 18, 2024